EUVIMEDEUVIMED entdecken
Klinische StudieRandomisierte kontrollierte Studie

Fibrinogen catabolism in patients with type II and type IV hyperlipidemia. Effect of dietary and clofibrate treatment on laboratory findings.

A Fletcher, N Alkjaersig, G Schonfeld, J Witztum

Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · 1981

DOI: 10.1161/01.atv.1.3.202 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1981. Verfasst von A Fletcher und 3 weiteren Autor:innen. Die Arbeit wurde bisher 7-mal zitiert (Crossref). Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fibrinogen catabolism was studied by plasma fibrinogen chromatography and other methods in 99 subjects with hyperlipoproteinemia Types IIa, IIb, and IV, and in 24 control subjects with normal blood lipid values. Subjects with either a history of thromboembolic vascular disease or clinical evidence of atherosclerosis were excluded. Type II subjects (i.e., the combined group of Type IIa and IIb subjects) showed an elevation of plasma high molecular weight fibrinogen complexes, which is indicative of enhanced fibrin formation. They also showed an elevation of fibrinogen-first-derivative, which is indicative of fibrinogenolysis and increased plasma euglobulin activity. Subjects with Type IV hyperlipoproteinemia showed similar findings to those of Type II except that high molecular weight fibrinogen complex concentration was normal. Subsequently, 36 patients received a fat-controlled, low cholesterol diet and were studied in a blind, random, crossover study of dietary vs clofibrate treatment. Although total cholesterol and triglyceride levels fell significantly during the treatment periods, chromatographic findings of abnormal plasma fibrinogen remained unchanged.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdultCholesterolCholesterol, DietaryClofibrateFemaleFibrin Fibrinogen Degradation ProductsFibrinogenHumansHyperlipoproteinemia Type IIHyperlipoproteinemia Type IVMaleMiddle AgedTriglycerides

Substanzen

Cholesterol, DietaryFibrin Fibrinogen Degradation ProductsTriglyceridesFibrinogenCholesterolClofibrate

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Fletcher, A., Alkjaersig, N., Schonfeld, G., & Witztum, J. (1981). Fibrinogen catabolism in patients with type II and type IV hyperlipidemia. Effect of dietary and clofibrate treatment on laboratory findings. Arteriosclerosis: An Official Journal of the American Heart Association, Inc.. https://doi.org/10.1161/01.atv.1.3.202

Vancouver

Fletcher A, Alkjaersig N, Schonfeld G, Witztum J. Fibrinogen catabolism in patients with type II and type IV hyperlipidemia. Effect of dietary and clofibrate treatment on laboratory findings. Arteriosclerosis: An Official Journal of the American Heart Association, Inc.. 1981. doi:10.1161/01.atv.1.3.202

BibTeX
@article{Fletcher1981,
  author = {Fletcher, A and Alkjaersig, N and Schonfeld, G and Witztum, J},
  title = {Fibrinogen catabolism in patients with type II and type IV hyperlipidemia. Effect of dietary and clofibrate treatment on laboratory findings},
  journal = {Arteriosclerosis: An Official Journal of the American Heart Association, Inc.},
  year = {1981},
  doi = {10.1161/01.atv.1.3.202}
}
Kostenlos starten →